Leo International Precision Health AG (ISIN: DE0005490601) approved a capital increase from the company’s own funds at its Annual General Meeting on 12 June 2026 and completed the Commercial Register entry on 28 July 2026. A total of 78,844,000 bonus shares were allocated. The move is an internal equity structure adjustment and does not involve new financing, changes in earnings, or business changes.

The company published an offer document on 23 January 2026 and revised it on 13 July 2026. It plans to raise up to £20,000,000 through the issue of 1 pence ordinary shares, with an overallotment facility of up to a further £10,000,000. Following the issue, the company’s total voting rights will be 374,125,913. The announcement is a routine equity-financing disclosure under the UK Disclosure Guidance and Transparency Rules and does not involve a material change in operations or regulatory status.

Black Rock Coffee Bar (NASDAQ: BRCB) is facing a federal securities class action after its IPO disclosures allegedly failed to flag “sales transfer,” where new store openings cannibalize revenue from existing locations. After reporting Q1 results on May 12, 2026, management said the phenomenon created a 160-basis-point headwind to same-store sales growth, as same-store sales growth fell 44% sequentially and revenue growth slowed sharply. The stock dropped 30% the next day to $7.72, down more than 61% from the $20 IPO price, and the lawsuit was filed on June 18.

Embecta Corp. (NASDAQ: EMBC) reported fiscal second-quarter 2026 results on May 5, 2026, saying revenue fell by more than 14% year over year, well below its prior guidance of 0% to a 2% decline, and it sharply lowered its full-year outlook. The stock dropped 57.8% that day, falling to $3.90 from $9.25. Investors have filed a securities fraud class action on behalf of shareholders who bought shares between November 25, 2025 and May 4, 2026.

SES AI Corporation（NYSE: SES）因涉嫌在2025年1月29日至2026年3月4日期间虚假陈述与AISPEX、Hisun及Data Blanket等合作伙伴的业务实质，以及Molecular Universe平台收入真实性，遭投资者集体诉讼。2026年3月4日财报披露后，公司股价单日下跌36.8%至1.08美元。诉讼指称其2026年营收指引（3000万–3500万美元）远低于预期（5167万美元），且内部早已知悉物流障碍与合作伙伴无实际履约能力。

ArcelorMittal said it has entered a strategic collaboration with Amazon Web Services (AWS) to deploy AI and edge computing to optimise steel production across its global operations. The companies also signed a multiyear framework under which ArcelorMittal will supply lower-carbon XCarb® structural steel to Amazon facilities in Europe and the United Kingdom, as well as AWS data centres. The agreement is intended to support Amazon’s goal of reaching net-zero carbon by 2040 and strengthen its green infrastructure supply chain. The announcement did not include changes to ArcelorMittal’s financial guidance or capacity plans and carries no direct near-term earnings impact for AMZN.

Via Transportation (NYSE: VIA) is facing a proposed class action alleging its September 2025 IPO offering documents contained materially misleading statements and omissions. The suit claims the company failed to disclose a decline in Platform Annual RunRate Revenue per customer and regulatory and structural issues that hindered its ability to expand beyond microtransit in Germany. The complaint says these issues came to light through disclosures starting Nov. 13, 2025, followed by further statements on Feb. 27, 2026 and May 12, 2026. Shareholders seeking to be appointed lead plaintiff must apply by Aug. 10, 2026, according to The Gross Law Firm.

Roblox released its fiscal 2026 first-quarter results on April 30, 2026, sharply cutting its bookings growth guidance to 8–12% and acknowledging a significant drop in engagement tied to its age verification rollout. The company said the age verification pass rate among global daily active users rose only to 51%, well below expectations. After the disclosure, RBLX fell 18.33% in a single day, sliding from a $55.26 close on April 30 to $45.13 on May 1.

A U.S. law firm has filed a securities class action against Erasca, Inc. (NASDAQ: ERAS), alleging false and misleading statements about its drug candidate ERAS-0015. The suit covers investors who bought Erasca securities between Jan. 14, 2025 and April 26, 2026. It claims the company relied on improper benchmarking for preclinical data, faced patent-infringement risk, and lacked a scientific basis for optimistic statements, according to the complaint. The case has been filed but has not yet been certified as a class action.